Blueprint for antimicrobial hit discovery targeting metabolic networks

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 3, 2010, Pages 1082-1087

  Shen, Y ^a,b   Liu, J ^b   Estiua, G ^a   Isin, B ^b   Ahn, Y Y ^c,d   Lee, D S ^c,d,f   Barabasi A L ^c,d   Kapatral, V ^e   Wiest, O ^a   Oltvai, Z N ^b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Eintegrated Genomics Inc   (United States)

^f Inha University   (South Korea)

Author keywords

Antibiotics; Flux balance analysis; Virtual screening

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CERULENIN; ECI10; ECI11; ECI12; ECI13; ECI14; ECI16; ECI23; ECI8; ENZYME INHIBITOR; FATTY ACID; FDI10; FDI11; FDI12; FDI14; FDI15; FDI2; FDI7; FDI8; PLATENSIMYCIN; THIOLACTOMYCIN; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL METABOLISM; BACTERIAL STRAIN; BIOSYNTHESIS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; ESCHERICHIA COLI; FATTY ACIDS; MODELS, MOLECULAR; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

EID: 75749105082     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909181107     Document Type: Article

References (40)

1. Russ AP, Lampel S (2005) The druggable genome: An update. Drug Discovery Today, 10:1577-1579.
2. Orth AP, Batalov S, Perrone M, Chanda SK (2004) The promise of genomics to identify novel therapeutic targets. Expert Opin Ther Targets, 8:587-596.
3. Gardner TS, di Bernardo D, Lorenz D, Collins JJ (2003) Inferring genetic networks and identifying compound mode of action via expression profiling. Science, 301:102-105.
4. Lamb J, et al. (2006) The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 313:1929-1935.
5. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science, 325:1089-1093.
6. Klevens RM, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, J Am Med Assoc, 298:1763-1771.
7. Feist AM, et al. (2007) A genome-scale metabolic reconstruction for Escherichia coli K-12 MG1655 that accounts for 1260 ORFs and thermodynamic information. Mol Syst Biol, 3:121.
8. Almaas E, Oltvai ZN, Barabási A-L (2005) The activity reaction core and plasticity of metabolic networks. PLoS Comput Biol, 1(e68):61-67.
9. Lee D-S, et al. (2009) Comparative genome-scale metabolic reconstruction and flux balance analysis of multiple Staphylococcus aureus genomes identify novel antimicrobial drug targets. J Bacteriol, 191:4015-4024.
10. Baba T, et al. (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: The Keio collection. Mol Syst Biol, 2 2006.0008.
11. Gerdes SY, et al. (2003) Experimental determination and system-level analysis of essential genes in Escherichia coli MG1655. J Bacteriol, 185:5673-5684.
12. Kang Y, et al. (2004) Systematic mutagenesis of the Escherichia coli genome. J Bacteriol, 186:4921-4930.
13. Zhang Y-M, Rock CO (2008) Membrane lipid homeostasis in bacteria. Nat Rev Microbiol, 6:222-233.
14. Campbell JW, Cronan JE (2001) Escherichia coli FadR positively regulates transcription of the fabB fatty acid biosynthetic gene. J Bacteriol, 183:5982-5990.
15. Harder ME, Ladenson RC, Schimmel SD, Silbert DF (1974) Mutants of Escherichia coli with temperature-sensitive malonyl coenzyme A-acyl carrier protein transacylase. J Biol Chem, 249:7468-7475.
16. Brinster S, et al. (2009) Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 458:83-86.
17. Jones PG, Sura T, Harris M, Strother A (2003) Mupirocin resistance in clinical isolates of Staphylococcus aureus. Infect Control Hosp Epidemiol, 24:300-301.
18. Kazakova SV, et al. (2005) A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med, 352:468-475.
19. Keatinge-Clay AT, et al. (2003) Catalysis, specificity, and ACP docking site of Streptomyces coelicolor malonyl-CoA:ACP transacylase. Structure, 11:147-154.
20. Li Z, et al. (2007) The crystal structure of MCAT from Mycobacterium tuberculosis reveals three new catalytic models. J Mol Biol, 371:1075-1083.
21. Oefner C, Schulz H, D'Arcy A, Dale GE (2006) Mapping the active site of Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by protein crystallography. Acta Crystallogr, Sect D: Biol Crystallogr, 62:613-618.
22. Serre L, Verbree EC, Dauter Z, Stuitje AR, Derewenda ZS (1995) The Escherichia coli malonyl-CoA:acyl carrier protein transacylase at 1.5-A resolution. Crystal structure of a fatty acid synthase component. J Biol Chem, 270:12961-12964.
23. Maier T, Leibundgut M, Ban N (2008) The crystal structure of a mammalian fatty acid synthase. Science, 321:1315-1322.
24. Irwin JJ, Shoichet BK (2005) ZINC - A free database of commercially available compounds for virtual screening. J Chem Inf Model, 45:177-182.
25. Thompson DC, Humblet C, Joseph-McCarthy D (2008) Investigation of MM-PBSA rescoring of docking poses. J Chem Inf Model, 48:1081-1091.
26. Wang J, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 441:358-361.
27. Lehár J, Stockwell BR, Giaever G, Nislow C (2008) Combination chemical genetics. Nat Chem Biol, 4:674-681.
28. Wang J, et al. (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA, 104:7612-7616.
29. Molnos J, Gardiner R, Dale GE, Lange R (2003) A continuous coupled enzyme assay for bacterial malonyl-CoA:acyl carrier protein transacylase (FabD). Anal Biochem, 319:171-176.
30. Kodali S, Galgoci A, Singh SB, Wang J (2006) Gel-elongation assay for type II fatty acid synthesis. Nat Protoc 10.1038/nprot.2006.1134.
31. Woods GL, Washington JA (1995) Antibacterial susceptibility tests: Dilution and disk diffusion methods. Manual of Clinical Microbiology, ed Murray PR (ASM Press, Washington, DC).
32. Hahn WC, et al. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400:464-468.
33. Schadt EE, et al. (2005) An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet, 37:710-717.
34. Yang X, et al. (2009) Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet, 41:415-423.
35. Pawson T, Linding R (2008) Network medicine. FEBS Lett, 582:1266-1270.
36. Dwyer DJ, Kohanski MA, Collins JJ (2009) Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol, 12:482-489.
37. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell, 130:797-810.
38. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ (2008) Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell, 135:1153-1156.
39. Feist AM, HerrgardMJ, Thiele I, Reed JL, Palsson BO (2009) Reconstruction of biochemical networks in microorganisms. Nat Rev Microbiol, 7:129-143.
40. Ong S-E, et al. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci USA, 106:4617-4622.